Predict your next investment

HEALTHCARE | Biotechnology
pharmasset.com

See what CB Insights has to offer

Founded Year

1998

Stage

Acq - P2P | Acquired

Total Raised

$51.31M

Valuation

$0000 

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. Pharmasset's research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication.In January 2012, Pharmasset was acquired by Gilead Sciences. The valuation of Pharmasset was $11.2 billion.

Pharmasset Headquarter Location

303 College Road E A

Princeton, New Jersey, 08540,

United States

609-613-4100

Latest Pharmasset News

U.K.-based bit.bio secures €89.1M to expedite gene engineering technology to fight diseases

Nov 8, 2021

A new, prominent Board of Directors  The new round of funding adds several notable names to bit.bio’s board of directors, including monoclonal antibody innovator and Nobel-winning scientist Greg Winter, Amadeus Capital Partners co-founder Dr. Hermann Hauser, and Pharmasset and Roivant founder Alan S. Roemer. Please leave this field empty Want to stay on top of the latest rounds, coolest tech and hottest startups? Subscribe to our free, daily news blast and stay up-to-date! Check your inbox or spam folder to confirm your subscription.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Pharmasset Patents

Pharmasset has filed 8 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/4/2008

2/14/2012

Prodrugs, HIV/AIDS, Virology, Antivirals, Animal viral diseases

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

1/4/2008

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

2/14/2012

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Prodrugs, HIV/AIDS, Virology, Antivirals, Animal viral diseases

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.